
PharmaEngine Profile last edited on: 7/9/2013
Biopharmaceuticals & Biotherapeutics Year Founded
2003Last Involved Year
2011Key People / Management
Location Information
16F-2, No.237, Sung-Chiang Road, Jhongshan District
Taipei, TW 104
Taipei, TW 104
886-2-25158228 |
www.pharmaengine.com |
Public Profile
PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003 principally engaged in the research and development of anticancer drugs. The Company's anticancer drugs are used in the treatment of pancreas cancer, gastric cancer, large intestine and rectal cancer, lung cancer, as well as cerebral cancer. As of December 31, 2011, the Company obtained its major revenue from product warranty transfer fee.PharmaEngine adopts the business model of no research, development only and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. The lead project PEP02 (nanoliposomal irinotecan, aka MM-398) which was licensed to Merrimack Pharmaceuticals, Inc., (Cambridge, MA, USA), is in a global phase III study for the treatment of metastatic pancreatic cancer; the second is PEP503 (crystalline hafnium oxide, aka NBTXR3) from Nanobiotix, Inc. (Paris, France); and the third was a collaboration with Guangzhou BeBetter Medicine Technology, Co., Ltd. (Guangzhou, China).
Extent of SBIR involvement
Synopsis: Techseeker Business Condition
Headquartered
TaiwanEmployment
17Revenue
$1.8MPublic/Private
Publicly TradedStock Info
Taiwan : 4162Received SBIR $$
NoTechseeker firm in the news
There are no news available.